CD47 and hepatocellular carcinoma: Therefore, in HCC immunotherapy, the use of CD47-blocking agents can disrupt its binding, restore the phagocytic function of DCs, enhance their antigen processing and presentation capabilities, thereby activating DCs and enhancing the immune responses [27].